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Background: Elderly patients with stage I NSCLC who undergo surgical resection are at high risk of treat-
ment-related toxicity. Stereotactic body radiation therapy (SBRT) may provide an alternative treatment
with a favorable toxicity proﬁle.
Methods: A population-based registry in North-Holland was used to conduct a matched-pair analysis of
overall survival (OS) after surgery versus SBRT for elderly patients (age P75) who were diagnosed
between 2005 and 2007. Patients were matched by age, stage, gender, and treatment year; co-morbidity
data was not available. SBRT was delivered at two centers; 17 centers provided surgery.
Results: A total of 120 patients could be matched (60 surgery, 60 SBRT). Median age was 79 years, 67%
were male, and 64% had T1 disease. Median follow-up was 43 months. Thirty-day mortality was 8.3%
after surgery and 1.7% after SBRT. OS at one- and three-years was 75% and 60% after surgery, and 87%
and 42% after SBRT, respectively (log-rank p = 0.22). Limiting the analysis to SBRT patients with patholog-
ical conﬁrmation of disease and their matches revealed no signiﬁcant difference between groups.
Conclusion: Similar OS outcomes are achieved with surgery or SBRT for stage I NSCLC in elderly patients.
Comorbidity data and outcomes from centralized surgical programs are needed for more robust
conclusions.
 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license.
Radiotherapy and Oncology 101 (2011) 240–244The treatment of elderly patients with stage I non-small cell
lung cancer (NSCLC) presents a therapeutic challenge to patients
and clinicians. Although stage I NSCLC is localized and, therefore,
theoretically curable, treatment can be hampered by medical
co-morbidity, frailty, lack of access to care, or unwillingness to pur-
sue treatment on the part of the patient or physician [1,2]. As a
result, some patients do not receive curative-intent treatment [3]
and these untreated patients can have poor survival outcomes
[4]. Unfortunately, this clinical scenario is increasingly common:
lung cancer is already a disease of the elderly (with one-third of pa-
tients older than 75), and changing population demographics in
many countries are expected to further increase the number of
cases in elderly patients [1,5].
The introduction of stereotactic body radiation therapy (SBRT;
also known as stereotactic ablative radiotherapy) for stage I NSCLC
has led to an improvement in local control rates, with low inci-
dence of high-grade toxicity [6], even in patients with substantialltidisciplinary Symposium in
Radiation Oncology, London
E, London, Ontario, Canada
nder the Elsevier OA license.comorbidities [7]. Both the low toxicity and preservation of quality
of life in the elderly [8,9] indicate that SBRT could have major
advantages in elderly patients [10]. SBRT is particularly appealing
as 30-day surgical mortality rates of >7% have been reported in
patients aged 75 and older [3]. In contrast, mortality rates after
SBRT are very low and local control rates generally exceed 90%
when sufﬁciently high radiation doses are delivered [10–12]. The
introduction of SBRT, delivered in the outpatient setting, has been
associated with increased access to care in elderly patients with
stage I NSCLC, a decrease in the proportion of patients going un-
treated, and an improvement in survival at population level [13].
Radiotherapy has traditionally been considered a second-choice
treatment for lung cancer, indicated in patients who are unﬁt for
surgery or refuse to undergo an operation, with surgery reserved
for the ﬁttest subgroup of elderly patients [14]. However, the
encouraging outcomes reported after SBRT have prompted ran-
domized comparisons of surgery versus SBRT as ﬁrst line treatment
for patients with an operable stage I NSCLC [15,16]. A single-insti-
tution matched analysis found no signiﬁcant differences between
surgery and SBRT in local recurrence, disease-speciﬁc survival, or
overall survival outcomes [17]. In the present analysis, we used a
population-based matched-pair study design in order to compare
overall survival after SBRT versus surgery for elderly patients with
stage I NSCLC.
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The Amsterdam Cancer Registry is a population-based registry
[18,19] capturing data on all residents of the provinces of North-
Holland and Flevoland (population 3 million people, representing
18% of the Netherlands population). Data are collected on all
cancer patients, including demographics, stage, and treatment,
directly from patient records; however, staging investigations,
comorbidities, and performance status, are not captured. Type of
surgery is recorded, but speciﬁc details of radiotherapy are not
available in the database and were obtained for this study, along
with co-morbidities for SBRT patients, by linking with databases
from the two radiotherapy centers in the region providing SBRT;
seventeen surgical centers performed resections on the cohort of
patients included in this study. The registry is linked to municipal
death registries. Any deaths occurring before February 1, 2010
were captured in the database. Cause of death is not available.
The history of SBRT introduction in the region has been previ-
ously described [13]. In brief, SBRT was ﬁrst introduced in 2003,
whereas after 2005 it was considered widely available, offered at
two radiotherapy (RT) centers that treated more than 80% of all
stage I RT patients in the period between 2005 and 2007. These
two centers accepted referrals from hospitals not providing SBRT.
Criteria for management of lung cancer patients were in
accordance with Dutch practice guidelines, developed by multidis-
ciplinary teams and available online (www.oncoline.nl). SBRT pa-
tients were discussed at a multi-disciplinary thoracic oncology
tumor board before ﬁnal treatment decisions were made in order
to facilitate a consensus opinion regarding operability. Speciﬁc
physiological data (e.g. predicted post-operative forced expiratory
volume in 1 s) were not recorded in the databases.
Patients were included in this study if diagnosed with clinical
stage I NSCLC (UICC 5th and 6th editions) between 2005 and
2007, and were aged 75 or older at diagnosis. Patients were ex-
cluded if there was a previous history of lung cancer. All patients
studied had clinical stage I (cT1 or cT2) disease. Patients who
had cT1 or cT2 disease based on pre-operative investigations, but
were subsequently pathologically up-staged at surgery, were also
included in this analysis, to ensure an equal comparison with the
clinically staged SBRT patients.
Matched-pair analysis is a method to reduce bias in observa-
tional studies by creating two comparable groups with similar
baseline factors, thus reducing confounding [20,21]. From the pop-
ulation of patients receiving SBRT and surgery, patients were
matched 1:1 based on the following factors: age (within 3 years),
stage (T1 or T2), gender, and treatment year. If a match could not
be found, the patient was excluded. Matching was done using a
semi-automated method with Microsoft Access (Microsoft Corpo-
ration, Redmond, Washington, USA). The dataset used in theTable 1
Baseline characteristics of 120 matched elderly patients and 70 unmatched patients with st
radiation therapy; IQR: interquartile range.
Parameter Matched patients
Surgery
n = 60
SBRT
n = 60
Age (median, IQR) 79 (76–80) 79 (76–
Sex
Male 40 (67%) 40 (67%
Female 20 (33%) 20 (33%
cT-stage
cT1 39 (65%) 39 (65%
cT2 21 (35%) 21 (35%
Pathological conﬁrmation
Yes All 28 (47%
No 32 (53%matching process had encrypted unique patient identiﬁers and
outcomes variables were removed, to ensure that the matching
was done in a blinded fashion.
Kaplan–Meier estimates of overall survival (OS) from date of
diagnosis were created and differences compared using the log-
rank test. A separate pre-speciﬁed subgroup analysis was done to
compare OS among SBRT patients with pathological conﬁrmation
of disease and their corresponding surgical matches. All statistical
tests were two-sided, with a threshold of p 6 0.05 for statistical
signiﬁcance, and were done using STATA (version 10, StataCorp
LP, College Station, Texas, USA).Results
A total of 346 elderly patients were diagnosed with stage I
NSCLC in the provinces of North-Holland and Flevoland between
2005 and 2007, and treatment of these patients was as follows:
109 (32%) received surgery, 81 (23%) received SBRT, 65 (19%)
received standard conventional conformal RT, and 91 (26%) under-
went neither surgery nor RT. Of the 190 patients treated with
surgery or SBRT, a total of 120 patients (60 SBRT and 60 surgery)
were matched, according to the criteria above. Not all patients
could be matched, as there were insufﬁcient numbers of octogen-
arian surgery patients to match the older SBRT cohort. Baseline
patient characteristics by treatment modality for matched and un-
matched patients are shown in Table 1.
Median follow-up was 43 months. For patients undergoing
surgery, 49 (82%) underwent lobectomy (including two sleeve
lobectomies), two (3%) underwent pneumonectomy and nine (15%)
underwent sublobar excision. Thirty-six percent of the cT1-tumors
were upstaged after surgery, and 43% of cT2-tumorswere upstaged.
Two surgical patients (3%) received adjuvant chemotherapy.
SBRT doses were as follows: 51 patients received 60 Gy (either
in three fractions [n = 15 patients], ﬁve fractions [n = 29] or eight
fractions [n = 7]; at one center this was based on a risk-adapted
scheme [22]); eight patients received 54 Gy in three fractions;
one received 32 Gy in two fractions. Eighty-two percent of SBRT
patients (49/60) were considered medically unﬁt for surgery,
whereas the rest (18%, 11/60) were considered medically operable,
but had refused surgery. Reasons for inoperability included COPD
(22 cases), cardiovascular diseases (eight cases), combination of
COPD and cardiovascular diseases (seven cases), other cancers
(four cases) and poor general condition (eight cases).
A total of 61 deaths were recorded in the cohort: 26 in the sur-
gical group and 35 in the SBRT group. The 30-day mortality calcu-
lated from the start date of treatment was 8.3% for surgery (ﬁve
deaths) and 1.7% for SBRT (one death). Thirty-day mortality for
the surgical group was 2.6% (one death) for patients below ageage I NSCLC treated with surgery or stereotactic radiotherapy. SBRT: stereotactic body
Patients who were not matched
Surgery
n = 49
SBRT
n = 21
81) 76 (75–79) 83 (82–86)
) 35 (71%) 15 (71%)
) 14 (29%) 6 (29%)
) 19 (39%) 19 (90%)
) 30 (61%) 2 (10%)
) All 5 (24%)
) 16 (76%)
Fig. 1. Overall survival (OS) for 120 elderly patients (age P75) with stage I NSCLC by treatment. There was no difference in OS between surgery and SBRT (log-rank test
p = 0.22).
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the respective 30-mortality rates were 0% and 4.4%.
OS at 1 year was 75% after surgery and 87% after SBRT. At
3 years, OS was 60% after surgery and 42% after SBRT. There was
no signiﬁcant difference between surgery and SBRT (Fig. 1; log-
rank p = 0.22).
The subgroup analysis comparing SBRT patients with patholog-
ical conﬁrmation of disease (47%) and their matched pairs is shown
in Fig. 2. Results were similar to the whole group analysis: OS at
1 year was 78% after surgery and 82% after SBRT; at 3 years, OS
was 61% after surgery and 47% after SBRT, with no signiﬁcant
difference between the two groups (log-rank p = 0.36).Discussion
This current matched-pair analysis of surgery versus SBRT for
stage I NSCLC using population-based data found no difference in
mortality between the two treatments. The survival patterns
shown here are compelling for a number of reasons. Firstly, more
than 80% of patients undergoing SBRT were considered unﬁt for
surgery due to medical co-morbidity, which in itself is associated
with a high risk of intercurrent death and a survival detriment of
10–20% at 5 years, when compared to patients who were operable
[23]. This suggests that SBRT OS outcomes would have been better
in a more ﬁt patient group. Secondly, SBRT, a non-invasive, out-pa-
tient treatment, has a low rate of 30-day mortality (<2% in this
study), despite the high-risk patient population treated. This
ﬁnding is of particular importance for patient decision making, as
patients are averse to taking risks that involve the possibility of
short-term death [24].
Importantly, the results of this study do not change if the cohort
is restricted to SBRT patients with pathological conﬁrmation of
disease and their surgical matches. Although pathological
conﬁrmation of disease should be sought wherever possible, in
many cases pulmonary function, frailty, or small lesion size
precludes trans-thoracic biopsy (or repeated biopsy if the ﬁrst is
indeterminate) [22,25]. In such cases, validated algorithms can beused to calculate malignancy risk based on history and ﬁndings
on CT and PET in that population [26]. In the North-Holland region,
use of clinical, PET and CT information achieves a low rate of
benign diagnosis at thoracotomy, [26–28] but selection of patients
using this approach could be inferior in geographic areas with
higher rates of benign infectious disease which may lead to false
positive PET scans. Furthermore, patients who do not undergo
biopsy in the North-Holland region have inferior survival
compared to those with a pathological diagnosis [13], a ﬁnding
that is likely to be due to intercurrent death from the underlying
co-morbid conditions that increased the risk of biopsy at the time
of diagnosis, conﬁrming that inclusion of patients without patho-
logical conﬁrmation of disease does not bias toward improved
survival results.
SBRT has several inherent advantages that may be appealing in
an elderly population: treatment times are short (3–8 fractions),
the side effect proﬁle is favorable, (with <10% of elderly patients
experiencing grade 3 or higher toxicity [10]) it is performed in an
outpatient setting, and hospitalization is rare. In contrast, surgical
intervention is associated with prolonged hospitalization and loss
of independence: nearly 25% of patients aged 80 and above are
not able to be discharged home after a lung resection [29].
This study is consistent with others that have been published
previously [17,30–32], and is a useful addition to the available
literature. Comparisons between surgery and SBRT have been ham-
pered by their retrospective nature and difﬁculty in controlling for
confounding variables; however, SBRT outcomes appear to be
similar to surgery if operable patients are studied [30,31], if
propensity score analysis is used to attempt control for such
confounders [17]. Comparable results for SBRT have also been
demonstrated in patients with severe COPD, another group at high
risk of surgical complications [33]. In comparison to wedge
resection, SBRT may achieve superior disease control, based on ret-
rospective data [32].
The relative effectiveness of surgery versus SBRT likely depends
on several features of the study population and the intervention. A
Markov-model based comparison of surgery versus SBRT for
patients aged 65 or 70 predicts that surgery confers an overall
Fig. 2. Overall survival (OS) for the subset of elderly SBRT patients (age P75) with pathological conﬁrmation of disease versus the corresponding matched patients who
underwent surgery. There was no difference in OS between surgery and SBRT (log-rank test p = 0.36).
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ative mortality increases above 4%, the survival advantage of sur-
gery is negated and SBRT is preferred [34].
Our study uses prospectively collected, population-based data
with outcomes that are always ascertainable through municipal
death records. Nevertheless, a number of limitations inherent to
a retrospective analysis must be kept in mind. A potential major
limitation of this comparison is the large number of institutions
performing resections (seventeen) in comparison to the number
of institutions performing SBRT (two). At the time these patients
were treated, surgical care was not yet centralized in the Nether-
lands. In general, hospitals performing the largest numbers of
resections carry out more thorough pre-operative staging [35],
and have signiﬁcantly lower post-operative mortality and better
5-year survival, compared to the lowest-volume hospitals [36]. It
is possible that after centralization of lung cancer surgery in the
Netherlands, post-operative survival will improve. In centralized
surgical centers, post-lobectomy mortality may be as low as
1–2%, depending on the ages and baseline characteristics of the pa-
tients [37]. It remains to be determined whether similar SBRT
results can be achieved at smaller centers, and this is the subject
of ongoing research.
Like many population-based databases, data were not available
on all baseline characteristics of interest (such as co-morbidities
for surgical patients, detailed reasons for inoperability for SBRT
patients, weight loss at presentation, performance status, and pul-
monary function tests) or all outcomes (such as cause of death,
cause-speciﬁc survival, local recurrence, or quality of life). Co-mor-
bidity has been shown to be a strong predictor of overall survival in
patients treated with SBRT [38]. In the current study, matching
allowed for the comparison of two groups that were equal in all
measured baseline factors, however, some of the unmeasured
variables may be confounders that could affect the results of the
study, and cannot be controlled for retrospectively. The lack of
baseline co-morbidity data is likely to bias the results against SBRT,
since the SBRT group is negatively selected by virtue of their high
comorbidity rates.
The rates of surgical upstaging in this series is consistentwith the
published literature: one study of patients with stage IA diseasebased on CT and PET staging reported upstaging at surgery in 35%
of patients; in patients with PET-positive tumors more than 2 cm
in size, the upstaging rate was 55% at surgery [39]. Finally, surgical
mortality rates may be lower in specialized, higher volume institu-
tions that report single institution results; the surgical mortality re-
ported here is consistent with other population-based studies [4].
Due to the differences in the populations of patients undergoing
SBRT or surgery, not all patients could be matched: there were
insufﬁcient old surgical patients to match some SBRT patients;
conversely, there were insufﬁcient young SBRT patients to match
some surgical patients. This resulted in a modest sample size, sim-
ilar to other comparisons of SBRT versus surgery [32]. Even if all
patients could have been matched, this study would be underpow-
ered to prove equivalence, a goal which would require nearly 1000
patients [40]. The comparison of SBRT versus surgery for elderly
patients can only be deﬁnitively answered in the context of a ran-
domized trial. However, one such trial has already closed due to
lack of accrual, and results from others are at least several years,
if accrual is successful. In the absence of such data from controlled
clinical trials, population-based data provide the next highest level
of evidence [41].
Although a lack of comorbidity data may bias the results against
SBRT, there are competing factors that may bias the results against
surgery, including the distributed nature of surgical care in the
province, and the potential for under-staging of surgical patients
at smaller centers. Furthermore, we cannot exclude a potential
beneﬁt for surgery in the long term, based on Figs. 1 and 2. In gen-
eral, the tails of Kaplan–Meier survival curves should not be used
to draw ﬁrm conclusions, since the numbers at risk are low at
those time points. Nonetheless, the data presented herein could
be consistent with better long-term survival after surgery than
after SBRT. If this is the case, there could be several potential expla-
nations, including differences in recurrence patterns, late toxicities,
or intercurrent deaths due to baseline co-morbid conditions; this
study cannot differentiate among these potential causes. Long term
outcomes after SBRT, including data on cause of deaths, require
future study as results mature.
In summary, this study suggests that in patients aged
P75 years, there is clinical equipoise as to the optimal ﬁrst-line
244 Stereotactic radiotherapy versus surgery in stage I NSCLCtreatment for stage I NSCLC; however, these conclusions would be
strengthened by further studies incorporating comorbidity data,
and outcomes from centralized surgical programs. The choice of
SBRT versus surgery might be best made at the individual patient
level, taking into account life expectancy, co-morbidity, operative
mortality risk, and quality of life. All patients should be informed
about the advantages and disadvantages of surgery and SBRT prior
to treatment.
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